ProAxsis announces that two of its products, the ProteaseTag® Active NE Immunoassay, and NEATstik®, the first test to enable measurement of active neutrophil elastase at point-of-care, have been selected for inclusion in a major upcoming clinical trial. The BRIDGE study is a 3-year collaborative study, funded by the European Respiratory Society (ERS), in which1000 patients with bronchiectasis across Europe will be recruited and will have multiple assessments including microbiome,proteomics, detailed phenotyping and imaging. The study will explore novel biomarkers and demonstrate what they can add to clinical practice. (Sept 2018)